The study published in NEJM entitled, “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors,” highlighted the antitumor activity of rezatapopt in heavily pretreated patients ...
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil. The prevalence of fibroadenoma-like areas in malignant phyllodes tumors of the ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...
The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...
Allo-HCT outcomes for TP53-mutated AML are similar across haploidentical, matched sibling, and matched unrelated donors. The study analyzed 451 patients, showing comparable 2-year overall survival and ...
Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results